Hillstream Biopharma (NASDAQ:CNTN) Trading 3.6% Higher – What’s Next?

Shares of Hillstream Biopharma Inc. (NASDAQ:CNTN) were up 3.6% on Monday . The stock traded as high as $2.03 and last traded at $2.00. Approximately 1,056,468 shares were traded during mid-day trading, an increase of 33% from the average daily volume of 795,892 shares. The stock had previously closed at $1.93.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CNTN. Wall Street Zen lowered Hillstream Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. Weiss Ratings downgraded shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Hillstream Biopharma Stock Down 0.5%

The firm’s 50 day moving average price is $2.56. The stock has a market capitalization of $146.53 million, a PE ratio of -1.65 and a beta of 1.45.

Insider Transactions at Hillstream Biopharma

In related news, Director Gary S. Stetz sold 87,851 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $3.42, for a total transaction of $300,450.42. Following the transaction, the director owned 146,675 shares in the company, valued at $501,628.50. The trade was a 37.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.34% of the stock is currently owned by corporate insiders.

About Hillstream Biopharma

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.